Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04010786 · ClinicalTrials.gov registry record · Phase 1
A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT04010786 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 103 participants.
The verdict
NCT04010786, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
This study looks at NNC0247-0829 (a potential new medicine) for weight management in people with overweight or obesity. The study looks at how NNC0247-0829 works in the body. Participants will either get NNC0247-0829 or placebo (a 'dummy' medicine) - which treatment is decided by chance. NNC0247-0829 is an experimental medicine which has not been approved by the US FDA. Participants will get either 1 injection or a total of 4 injections (one week apart) by a study nurse at the clinic depending on what group they are in. The study will last for about 18 months, but participation will last from 11 to 23 weeks. This will depend on the group participants are in. Participants will attend 8 to 14 visits at the clinic with the study staff. Some participants will have one 16-day, 15-night visit and one 2-day, 1-night visit. Others will have two 2-day, 1-night visits. At all visits except one, participants will have blood tests and other checks. They will be asked about their health, medical history and habits including mental health questionnaires.
Interventions
- DRUG NNC0247-0829
- DRUG Placebo (NNC0247-0829)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2019-07-11 |
| Est. Completion | 2022-06-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04010786
The ClinicalTrials.gov registry entry for NCT04010786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NNC0247-0829 is the first listed.
NCT04010786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04010786 about?
NCT04010786 is a clinical study titled "A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity". This study looks at NNC0247-0829 (a potential new medicine) for weight management in people with overweight or obesity. The study looks at how NNC0247-0829 works in the body. Participants will either get NNC0247-0829 or placebo (a 'dummy' medicine) - which treatment is decided by chance. NNC0247-082...
What is the current status of trial NCT04010786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2019-07-11. Estimated completion is 2022-06-21.
What interventions are being tested in trial NCT04010786?
The interventions under investigation include: NNC0247-0829 (DRUG), Placebo (NNC0247-0829) (DRUG).
Who is sponsoring clinical trial NCT04010786?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.